Sorafenib-induced	sorafenib-induced	O	O	O	O
acute	acute	O	DISEASE	OTHERS	I
myocardial	myocardial	O	DISEASE	OTHERS	I
infarction	infarction	O	DISEASE	OTHERS	I
due	due	O	O	O	O
to	to	O	O	O	O
coronary	coronary	O	O	OTHERS	I
artery	artery	O	O	OTHERS	I
spasm	spasm	O	DISEASE	OTHERS	I
.	.	O	O	O	O

A	a	O	O	O	O
65-year-old	65-year-old	O	O	O	O
man	man	O	O	O	O
with	with	O	O	O	O
advanced	advanced	O	O	O	O
renal	renal	O	O	OTHERS	I
cell	cell	O	O	OTHERS	I
carcinoma	carcinoma	O	DISEASE	OTHERS	I
was	was	O	O	O	O
admitted	admitted	O	O	O	O
due	due	O	O	O	O
to	to	O	O	O	O
continuing	continuing	O	O	O	O
chest	chest	O	DISEASE	OTHERS	I
pain	pain	O	DISEASE	OTHERS	I
at	at	O	O	O	O
rest	rest	O	O	O	O
.	.	O	O	O	O

Two	two	O	O	O	O
weeks	weeks	O	O	O	O
before	before	O	O	O	O
his	his	O	O	O	O
admission	admission	O	O	O	O
,	,	O	O	O	O
sorafenib	sorafenib	CHEMICALS	O	OTHERS	I
had	had	O	O	O	O
been	been	O	O	O	O
started	started	O	O	O	O
.	.	O	O	O	O

He	he	O	O	O	O
was	was	O	O	O	O
diagnosed	diagnosed	O	O	O	O
with	with	O	O	O	O
non-ST-elevation	non-st-elevation	O	O	O	O
myocardial	myocardial	O	DISEASE	OTHERS	I
infarction	infarction	O	DISEASE	OTHERS	I
by	by	O	O	O	O
laboratory	laboratory	O	O	O	O
data	data	O	O	O	O
and	and	O	O	O	O
electrocardiogram	electrocardiogram	O	O	O	O
.	.	O	O	O	O

Enhanced	enhanced	O	O	O	O
heart	heart	O	O	O	O
magnetic	magnetic	O	O	O	O
resonance	resonance	O	O	O	O
imaging	imaging	O	O	O	O
also	also	O	O	O	O
showed	showed	O	O	O	O
subendocardial	subendocardial	O	O	OTHERS	I
infarction	infarction	O	DISEASE	OTHERS	I
.	.	O	O	O	O

However	however	O	O	O	O
,	,	O	O	O	O
there	there	O	O	O	O
was	was	O	O	O	O
no	no	O	O	O	O
stenosis	stenosis	O	O	OTHERS	I
in	in	O	O	O	O
coronary	coronary	O	O	O	O
arteries	arteries	O	O	O	O
on	on	O	O	O	O
angiography	angiography	O	O	O	O
.	.	O	O	O	O

Coronary	coronary	O	O	OTHERS	I
artery	artery	O	O	OTHERS	I
spasm	spasm	O	DISEASE	OTHERS	I
was	was	O	O	O	O
induced	induced	O	O	O	O
by	by	O	O	O	O
a	a	O	O	O	O
provocative	provocative	O	O	O	O
test	test	O	O	O	O
.	.	O	O	O	O

Cessation	cessation	O	O	O	O
of	of	O	O	O	O
sorafenib	sorafenib	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
administration	administration	O	O	O	O
of	of	O	O	O	O
Ca-channel	ca-channel	O	O	O	O
blocker	blocker	O	O	O	O
and	and	O	O	O	O
nitrates	nitrates	O	O	OTHERS	I
ameliorated	ameliorated	O	O	O	O
his	his	O	O	O	O
symptoms	symptoms	O	O	O	O
,	,	O	O	O	O
but	but	O	O	O	O
relapse	relapse	O	O	O	O
occurred	occurred	O	O	O	O
after	after	O	O	O	O
resumption	resumption	O	O	O	O
of	of	O	O	O	O
sorafenib	sorafenib	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Addition	addition	O	O	O	O
of	of	O	O	O	O
oral	oral	O	O	O	O
nicorandil	nicorandil	O	O	OTHERS	I
reduced	reduced	O	O	O	O
his	his	O	O	O	O
symptoms	symptoms	O	O	O	O
and	and	O	O	O	O
maintained	maintained	O	O	O	O
stable	stable	O	O	OTHERS	I
angina	angina	O	O	OTHERS	I
status	status	O	O	O	O
.	.	O	O	O	O

We	we	O	O	O	O
report	report	O	O	O	O
the	the	O	O	O	O
first	first	O	O	O	O
case	case	O	O	O	O
of	of	O	O	O	O
sorafenib-induced	sorafenib-induced	O	O	O	O
coronary	coronary	O	O	OTHERS	I
artery	artery	O	O	OTHERS	I
spasm	spasm	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Sorafenib	sorafenib	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
a	a	O	O	O	O
multikinase	multikinase	O	O	O	O
inhibitor	inhibitor	O	O	O	O
that	that	O	O	O	O
targets	targets	O	O	O	O
signaling	signaling	O	O	O	O
pathways	pathways	O	O	O	O
necessary	necessary	O	O	O	O
for	for	O	O	O	O
cellular	cellular	O	O	O	O
proliferation	proliferation	O	O	O	O
and	and	O	O	O	O
survival	survival	O	O	O	O
.	.	O	O	O	O

On	on	O	O	O	O
the	the	O	O	O	O
other	other	O	O	O	O
hand	hand	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
Rho/ROCK	rho/rock	O	O	O	O
pathway	pathway	O	O	O	O
has	has	O	O	O	O
an	an	O	O	O	O
important	important	O	O	O	O
role	role	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
pathogenesis	pathogenesis	O	O	O	O
of	of	O	O	O	O
coronary	coronary	O	O	OTHERS	I
artery	artery	O	O	OTHERS	I
spasm	spasm	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Our	our	O	O	O	O
report	report	O	O	O	O
may	may	O	O	O	O
show	show	O	O	O	O
an	an	O	O	O	O
adverse	adverse	O	O	O	O
effect	effect	O	O	O	O
on	on	O	O	O	O
the	the	O	O	O	O
Rho/ROCK	rho/rock	O	O	O	O
pathway	pathway	O	O	O	O
by	by	O	O	O	O
sorafenib	sorafenib	CHEMICALS	O	OTHERS	I
use	use	O	O	O	O
.	.	O	O	O	O

